Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $40.0K | $325.0K | $449.0K | $218.0K | $396.0K | $2.1M | $5.5M | $12.7M |
| Cost of revenue | $240.0K | $493.0K | $463.0K | $189.0K | $258.0K | $1.4M | $4.3M | $7.0M |
| Gross profit | −$200.0K | −$168.0K | −$14.0K | $29.0K | $138.0K | $670.0K | $1.2M | $5.6M |
| Gross margin | -500.0% | -51.7% | -3.1% | 13.3% | 34.8% | 31.9% | 22.2% | 44.5% |
| R&D | $388.0K | $429.0K | $553.0K | $1.3M | $1.3M | $4.1M | $2.3M | $3.4M |
| Operating income | −$93.3K | −$159.9K | −$2.0M | −$2.3M | −$6.2M | −$8.5M | −$10.6M | −$10.0M |
| EBITDA | −$2.1M | −$1.7M | −$2.0M | −$2.0M | −$5.8M | −$8.6M | −$9.1M | −$9.8M |
| Net income | −$3.5M | −$1.8M | −$6.7M | −$5.3M | −$6.6M | −$9.8M | −$11.2M | −$12.6M |
| Net margin | -8747.5% | -568.0% | -1486.2% | -2435.8% | -1662.6% | -467.5% | -204.4% | -99.1% |
| EPS (diluted) | -0.24 | -0.09 | -16.80 | -1.80 | -0.68 | -0.79 | -0.86 | -0.93 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds CNVCF.
No tracked institution reports a position in CNVCF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-06-03 | 1-for-35reverse |
No one on the platform has traded CNVCF yet.
| $99M |
| — |
| EOFBYEcofibre Limited | $0.84 | +0.00% | $74M | — |
| EPRXFEupraxia Pharmaceuticals Inc. | $3.04 | -6.17% | $108M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 6.9× sales vs its 20.8× historical median P/S.
Fair value ≈ $17.35 · price $5.71 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$BHST I got an absolutely incredible response from Justin at BioHarvest after asking about the competitive landscape that BioHarvest exists in. One of the best IR teams I’ve come across. I know it won’t stay that way for long as they will soon be dealing with hundreds of thousands of questions but I recommend you take advantage of the opportunity while it is there.
View on StockTwits ↗$BHST Someone with a science background explain how $CANSF differs in approach
View on StockTwits ↗$BHST $3M to build a bioreactor that generates $40M in annual revenue. Infinitely scalable tech. $500B TAM
View on StockTwits ↗$BHST can't wait for tons of youtube creators to make Bioharvest Science inc content
View on StockTwits ↗$BHST https://www.theglobeandmail.com/business/article-canadian-israeli-biotech-company-growing-nutrients-for-earth-and/
View on StockTwits ↗$BHST can’t wait until more find this stock 2022 breakout year
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.